抗吸收药物对已骨结合牙种植体存留及种植体周围炎的影响:回顾性队列研究
该回顾性队列研究纳入80例抗吸收药物(ARD)使用者(344枚种植体)和80例非使用者,随访平均85.3个月。ARD组种植体存留率89.83%,非ARD组96.03%。ARD使用与种植体失败风险升高相关,风险因素包括已有边缘骨吸收、糖尿病、覆盖义齿及种植体植入至ARD开始间隔短。
要点
- ARD使用者种植体存留率低于非使用者(89.83% vs 96.03%)。
- 已有边缘骨吸收、糖尿病、覆盖义齿及短间隔(<36个月)增加失败风险。
- 固定夹板修复较覆盖义齿失败风险更低。
核心结论
- 种植体骨结合后使用ARD与种植体存留率降低相关。
- 已有边缘骨吸收、糖尿病、最终修复体类型及种植体植入至ARD起始间隔影响种植体失败风险。
研究设计与样本
- 回顾性队列研究,纳入2008至2017年间80例ARD使用者(344枚种植体,随访>12个月)和80例非ARD使用者。
- 主要结局为牙种植体存留,采用Kaplan-Meier生存曲线和Cox比例风险模型分析。
主要发现
- 平均随访85.3个月,ARD组种植体存留率89.83%,非ARD组96.03%。
- 单因素Cox模型显示已有边缘骨吸收、糖尿病和同期骨增量患者种植体失败风险显著更高。
- 种植体植入至ARD给药间隔<36个月时失败风险显著更低。
- 与覆盖义齿相比,单冠和固定夹板修复者种植体失败风险更低。
- 多因素分析中,已有边缘骨吸收、糖尿病、间隔<36个月和固定夹板修复与种植体失败风险增加显著相关。
关键数值与推荐
- ARD使用者种植体存留率89.83%,非ARD使用者96.03%。
- 平均随访85.3个月。
- 种植体植入至ARD给药间隔<36个月与失败风险降低相关(单因素),但在多因素中与风险增加相关。
临床怎么用
- 对已有骨结合种植体的患者启用ARD前,应评估边缘骨吸收、糖尿病及修复体类型等风险因素。
- ARD使用期间需加强种植体存留监测,尤其对合并糖尿病或已有边缘骨吸收者。
局限性
- 回顾性设计可能存在选择偏倚和混杂因素。
- 样本量有限(每组80例),结论需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: The effect of anti-resorptive drug (ARD) usage among patients with successful dental implant osseointegration is controversial. This study showed an increased risk of implant failure in ARD users. Risk factors included pre-existing marginal bone loss, overdenture, diabetes, and a short interval between implant placement and ARD administration. INTRODUCTION: This retrospective study aimed to determine whether anti-resorptive drug (ARD) usage increased risk of implant failure among patients with successful implant osseointegration. Additionally, the study investigated risk factors that affected implant survival rate in ARD users. METHODS: Eighty ARD users with 344 implants who had more than 12 months of follow-up from the initiation of ARD treatment during the period between 2008 and 2017 were included, along with 80 non-ARD users from the same period. The primary outcome was dental implant survival. Kaplan-Meier survival curves and Cox proportional hazard models were used for survival analysis. RESULTS: Average follow-up was 85.3 months. Implant survival rates were 89.83% in ARD users and 96.03% in non-ARD users. In the univariate Cox proportional hazard model, risk of implant failure was significantly higher in patients with pre-existing marginal bone loss (MBL), diabetes, and concurrent bone augmentation. However, risk of implant failure was significantly lower when the interval between implant placement and ARD administration was < 36 months. Compared with overdenture, single crown and fixed splinted users had lower risk of implant failure. In multivariate analysis, variables including pre-existing MBL, diabetes, < 36-month interval between implant placement and ARD treatment, and usage of fixed splinted prosthesis were significantly associated with increased risk of implant failure. CONCLUSIONS: ARD administration after implant osseointegration was correlated with a reduced implant survival rate. Pre-existing MBL, diabetes, type of final prosthesis, and the interval between implant placement and initiation of ARD administration influenced risk of implant failure.
引用
- Kim JY, Choi H, Park JH, et al. Effects of anti-resorptive drugs on implant survival and peri-implantitis in patients with existing osseointegrated dental implants: a retrospective cohort study. Osteoporos Int. 2020. PMID: 32367226. doi:10.1007/s00198-019-05257-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。